Clinical Impact of New Data From AASLD 2019

November 8-12, 2019; Boston, Massachusetts
This downloadable slideset reviews new, clinically relevant data on viral hepatitis and NAFLD/NASH; topics include risk of HCC in patients with viral hepatitis, HBV and HCV treatment, organ transplant from donors with HCV infection, and novel treatments for NAFLD/NASH.
Ira M. Jacobson, MD
Nancy Reau, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 894 KB
Released: December 2, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Dr Paul Kwo discusses evolving treatment options for hepatitis delta virus (HDV), from Clinical Care Options (CCO)

Paul Y. Kwo, MD Released: August 2, 2022

Download slides reviewing the latest data and guidance on approaches to managing patients with hepatitis delta virus (HDV), from Clinical Care Options (CCO)

person default Joseph (Patient) Maria Buti, MD person default Richard H. Davis, PA-C Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 25, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Clinical Care Options (CCO) expert analysis by Prof Tarik Asselah on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Tarik Asselah, MD, PhD Released: July 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings